Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Plantronics, Lipocine, Armstrong Flooring, and Wanda Sports Group and Encourages Investors to Contact the Firm

NEW YORK, Dec. 04, 2019 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of Plantronics, Inc. (NYSE: PLT), Lipocine, Inc. (NASDAQ: LPCN), Armstrong Flooring, Inc (NYSE: AFI), and Wanda Sports Group Company Limited (NASDAQ: WSG). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Plantronics, Inc. (NYSE: PLT)Class Period: July 2, 2018 to November 5, 2019Lead Plaintiff Deadline: January 13, 2020On November 5, 2019, the Company disclosed a $65 million reduction in channel inventory “by reducing sales to channel partners” and decreased its fiscal 2020 guidance, expecting revenue between $1.72 billion and $1.81 billion and adjusted EBITDA between $282 million and $323 million. Plantronics also reported that its Executive Vice President of Global Sales was leaving the Company.On this news, the Company’s stock price fell $14.44 per share, or nearly 37%, to close at $25.00 per share on November 6, 2019.The complaint, filed on November 13, 2019, alleges that throughout the Class Period defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, defendants failed to disclose to investors: (1) that the Company had engaged in channel stuffing to artificially boost sales; (2) that the Company’s internal control over inventory levels was not effective; (3) that the Company had not adequately monitored inventory levels ahead of multiple product launches, where the new models would displace demand for aging products; and (4) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.For more information on the Plantronics class action go to: https://bespc.com/pltLipocine, Inc. (NASDAQ: LPCN)Class Period: March 27, 2019 to November 8, 2019Lead Plaintiff Deadline: January 14, 2020Lipocine’s lead product candidate is TLANDO (LPCN 1021), an oral testosterone replacement therapy.  The Company has previously submitted New Drug Applications (“NDA”) for TLANDO twice and, both times, received Complete Response Letters (“CRL”) from the U.S. Food and Drug Administration (“FDA”) rejecting the NDAs.  The Company received the first CRL in June 2016 and the second in May 2018.On March 27, 2019, Lipocine issued a press release announcing new topline results from a study evaluating TLANDO’s effects on blood pressure (one issue cited by the FDA in a prior CRL rejecting TLANDO’s NDA), as well as the Company’s intention to refile the NDA for TLANDO in the second quarter of 2019.On November 11, 2019, Lipocine issued a press release announcing receipt of a CRL from the FDA regarding its NDA for TLANDO.  In the press release, Lipocine advised investors that the FDA had again rejected the NDA for TLANDO—this time because an efficacy trial had not met three of its secondary endpoints.On this news, Lipocine’s stock price fell $1.93 per share, or 70.7%, to close at $0.80 per share on November 11, 2019.The Complaint, filed on November 14, 2019, alleges that throughout the Class Period defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies.  Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) the results from Lipocine’s clinical studies of TLANDO were insufficient to demonstrate the drug’s efficacy; (ii) accordingly, Lipocine’s third NDA for TLANDO was highly likely to be found deficient by the FDA; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.For more information on the Lipocine class action go to: https://bespc.com/lpcnArmstrong Flooring, Inc. (NYSE: AFI)Class Period: March 6, 2018 to November 4, 2019Lead Plaintiff Deadline: January 14, 2020On May 3, 2019, Armstrong Flooring’s Chief Executive Officer abruptly resigned.On this news, the Company’s stock price fell $1.75, nearly 12%, to close at $13.14 per share on May 3, 2019.Then, on November 5, 2019, Armstrong Flooring reported $165.6 million net sales for third quarter 2019, a nearly 21% decline year-over-year, and a net loss of $31.4 million. The Company also cut its full year 2019 guidance for adjusted EBITDA to a range of $20 million to $25 million, from prior guidance range of $46 million to $54 million, citing “larger distributor movements on inventory” than anticipated.On this news, the Company’s stock price fell $2.90 per share, or nearly 44%, to close at $3.70 per share on November 5, 2019.The complaint, filed on November 15, 2019, alleges that throughout the Class Period defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, defendants failed to disclose to investors: (1) that the Company had engaged in channel stuffing to artificially boost sales; (2) that the Company’s internal control over inventory levels was not effective; and (3) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.For more information on the Armstrong Flooring class action go to: https://bespc.com/afiWanda Sports Group Company Limited (NASDAQ: WSG)Class Period: Securities purchased pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration Statement”) issued in connection with Wanda Sports’ July 26, 2019 initial public offering (“IPO”).Lead Plaintiff Deadline: January 17, 2020In July 2019, Wanda Sports held its IPO, issuing approximately 23.8 million American Depository Shares (“ADSs”) at $8.00 per share, pursuant to the Registration Statement. Wanda Sports’ shares have lost nearly 60% of their value, closing at $2.78 on November 18, 2019.The complaint, filed on November 18, 2019, alleges that defendants made statements that were materially false and/or misleading because they misrepresented and failed to disclose the following adverse facts pertaining to the Company’s business, operations and prospects: (1) the lack of major sporting events for its DPSS and Spectator Sports segments for its second quarter of 2019, ending before the IPO, would negatively impact revenue for the second quarter of 2019; (2) Wanda Sports had suffered a year-over-year decrease in revenue in its second quarter ended June 30, 2019 and would for its fiscal year 2019, primarily related to lower reimbursement revenues accounted for in its DPSS segment and lack of Spectator Sport segment offsets; and (3) as a result, defendants’ statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.For more information on the Wanda Sports class action go to: https://bespc.com/wsgAbout Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com.  Attorney advertising.  Prior results do not guarantee similar outcomes. 
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
(212) 355-4648
[email protected]
www.bespc.com

Wall St Business News, Latest and Up-to-date Business Stories from Newsmakers of Tomorrow

Wall Street Business News

Start typing and press Enter to search